Pain in Parkinson’s disease (PD) is a debilitating symptom with a prevalence of 68%, yet is untreated 50% of the time. What is unclear, however, is which treatment is optimal for minimizing pain severity in PD. Thus, the objective of this systematic review and meta-analysis was to investigate the efficacy of a variety of novel, complimentary, and conventional treatments for pain in PD and elucidate which therapy is the most effective. A systematic search was performed using MEDLINE, PsycINFO, Embase, CINAHL, and CENTRAL databases. To identify additional articles, manual searches of reference lists of included trials were also searched. Major neurology conference proceedings occurring between January 2014 and February 2018 were also searched to identify unpublished studies that may be potentially eligible. Twenty-five randomized controlled trials that encompassed medical, surgical, and complementary therapies met our inclusion criteria and exhibited moderate quality evidence. Two reviewers conducted assessments for study eligibility, risk of bias, data extraction, and quality of evidence rating. A conservative random-effects model was used to pool effect estimates of pain severity. The greatest reductions in pain were found with safinamide (Standardized mean difference = –4.83, 95% CI [–5.07 to –4.59], p < 0.0001), followed by cannabinoids and opioids, multidisciplinary team care, catechol-O-methyltransferase inhibitors, and electrical and Chinese therapies. Moderate effects in reducing pain were in pardoprunox and surgery, while the weakest effects were in dopaminergic agonists and miscellaneous therapies. Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD.

1.
Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X: Projection of the prevalence of Parkinson's disease in the coming decades: revisited. Mov Disord 2018; 33: 156–159.
2.
Nussbaum RL, Ellis CE: Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003; 348: 1356–1364.
3.
De Lau LM, Breteler MM: Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5: 525–535.
4.
Buhmann C, Wrobel N, Grashorn W, Fruendt O, Wesemann K, Diedrich S, Bingel U. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol 2017; 264: 758–769.
5.
Broen MP, Braaksma MM, Patijn J, Weber WE: Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord 2012; 27: 480–484.
6.
Beiske AG, Loge JH, Rønningen A, Svensson E: Pain in Parkinson's disease: prevalence and characteristics. Pain 2009; 141: 173–177.
7.
Valkovic P, Minar M, Singliarova H, Harsany J, Hanakova M, Martinkova J, Benetin J: Pain in Parkinson’s disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life. PLoS One 2015; 10:e0136541.
8.
Ehrt U, Larsen JP, Aarsland D: Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry 2009; 17: 269–275.
9.
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri K: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399–406.
10.
Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006; 5: 235–245.
11.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
12.
Higgins JP. Green S: Cochrane handbook for systematic reviews of interventions -version 5.1. 0. The cochrane collaboration 2011; 5.
13.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–174.
14.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
15.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
16.
Cattaneo C, Barone P, Bonizzoni E, Sardina M: Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. J Parkinsons Dis 2017; 7: 95–101.
17.
Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–580.
18.
Rascol O, Zesiewicz T, Chaudhuri K, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L: A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease-associated chronic pain. J Clin Pharmacol 2016; 56: 852–861.
19.
Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J: Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90–99.
20.
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP: Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004; 63: 1245–1250.
21.
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A: Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurology 2015; 14): 1161–1170.
22.
Charles D, Konrad PE, Neimat JS, Molinari AL, Tramontana MG, Finder SG, Gill CE, Bliton MJ, Kao C, Phibbs FT, Hedera P: Subthalamic nucleus deep brain stimulation in early stage Parkinson’s disease. Parkinsonism Relat Disord 2014; 20: 731–737.
23.
Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S: Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010; 9: 581–591.
24.
De Bie RM, de Haan RJ, Nijssen PC, Rutgers AW, Beute GN, Bosch DA, Haaxma R, Schmand B, Schuurman PR, Staal MJ, Speelman JD: Unilateral pallidotomy in Parkinson’s disease: a randomised, single-blind, multicentre trial. Lancet 1999; 354: 1665–1669.
25.
Chua KK, Wong A, Chan KW, Lau YK, Bian ZX, Lu JH, Liu LF, Chen LL, Chan KH, Tse KP, Chan A, et al: A randomized controlled trial of Chinese medicine on nonmotor symptoms in Parkinson’s disease. Parkinsons Dis 2017; 2017: 1902708.
26.
Jitkritsadakul O, Thanawattano C, Anan C, Bhidayasiri R: Tremor’s glove-an innovative electrical muscle stimulation therapy for intractable tremor in Parkinson’s disease: a randomized sham-controlled trial. J Neurol Sci 2017; 381: 331–340.
27.
Lei H, Toosizadeh N, Schwenk M, Sherman S, Karp S, Sternberg E, Najafi B: A pilot clinical trial to objectively assess the efficacy of electroacupuncture on gait in patients with Parkinson’s disease using body worn sensors. PLoS One 2016; 11:e0155613.
28.
Rintala DH, Tan G, Willson P, Bryant MS, Lai EC: Feasibility of using cranial electrotherapy stimulation for pain in persons with Parkinson’s disease. Parkinsons Dis 2010; 2010: 569154.
29.
Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O, Theeuwes A, Van De Witte SV. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson’s disease. Eur Neurol 2009; 62: 40–48.
30.
Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, Van de Witte SV: Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012; 18: 370–376.
31.
Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004; 61: 1563–1568.
32.
Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M: Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord 2013; 28: 605–611.
33.
Pérez de la Cruz S: Effectiveness of aquatic therapy for the control of pain and increased functionality in people with Parkinson’s disease: a randomized clinical trial. Eur J Phys Rehabil Med 2017; 53: 825–832.
34.
Volpe D, Giantin MG, Manuela P, Filippetto C, Pelosin E, Abbruzzese G, Antonini A: Water-based vs. non-water-based physiotherapy for rehabilitation of postural deformities in Parkinson’s disease: a randomized controlled pilot study. Clin Rehabil 2017; 31: 1107–1115.
35.
Skogar Ö, Borg A, Larsson B, Robertsson L, Andersson L, Backstrom P, Fall PA, Hallgren G, Bringer B, Carlsson M, Lennartsson U: “Effects of Tactile Touch on pain, sleep and health related quality of life in Parkinson’s disease with chronic pain”: a randomized, controlled and prospective study. Eur J Integrat Med 2013; 5: 141–152.
36.
Poliakoff E, Galpin AJ, McDonald K, Kellett M, Dick JP, Hayes S, Wearden AJ: The effect of gym training on multiple outcomes in Parkinson’s disease: a pilot randomised waiting-list controlled trial. NeuroRehabilitation 2013; 32: 125–134.
37.
Pickut B, Vanneste S, Hirsch MA, Van Hecke W, Kerckhofs E, Mariën P, Parizel PM, Crosiers D, Cras P: Mindfulness training among individuals with Parkinson’s disease: neurobehavioral effects. Parkinsons Dis 2015; 2015: 816404.
38.
Kapur SS, Stebbins GT, Goetz CG: Vibration therapy for Parkinson’s disease: Charcot’s studies revisited. J Parkinsons Dis 2012; 2: 23–27.
39.
Ni M, Mooney K, Signorile JF: Controlled pilot study of the effects of power yoga in Parkinson’s disease. Complement Ther Med 2016; 25: 126–131.
40.
Blair HA, Dhillon S: Safinamide: a review in parkinson’s disease. CNS Drugs 2017; 31: 169–176.
41.
Schapira A, Fox S, Hauser R, Jankovic J, Jost W, Kulisevsky J, Pahwa R, Poewe W, Anand R: Safinamide add on to L-Dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson’s disease (PD) and motor fluctuations (SETTLE)(P01. 062). Neurology 2013; 80(7 Suppl):P01–062.
42.
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P: Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 2014; 29: 1273–1280.
43.
Manzanares J, Julian MD, Carrascosa A: Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006; 4: 239–257.
44.
Quinn NP, Lang AE, Koller WC, Marsden CD: Painful Parkinson’s disease. Lancet 1986; 327: 1366–1369.
45.
Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O: Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008; 23: 1361–1369.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.